The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study

Sergio D Bergese, Erika G Puente, Maria A Antor, Gerardo Capo, Vedat O Yildiz, Alberto A Uribe, Sergio D Bergese, Erika G Puente, Maria A Antor, Gerardo Capo, Vedat O Yildiz, Alberto A Uribe

Abstract

Introduction: Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical patients during the first 24 h after a surgical procedure. The incidence of postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about 30%, and in high-risk patients, the PONV rate could be as high as 80%. Therefore, the study design of this single arm, non-randomized, pilot study assessed the efficacy and safety profile of a triple therapy combination with palonosetron, dexamethasone, and promethazine to prevent PONV in patients undergoing craniotomies under general anesthesia.

Methods: The research protocol was approved by the institutional review board and 40 subjects were provided written informed consent. At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV, and promethazine 25 mg IV was given as PONV prophylaxis. After surgery, subjects were transferred to the surgical intensive care unit or post anesthesia care unit as clinically indicated. Ondansetron 4 mg IV was administered as primary rescue medication to subjects with PONV symptoms. PONV was assessed and collected every 24 h for 5 days via direct interview and/or medical charts review.

Results: The overall incidence of PONV during the first 24 h after surgery was 30% (n = 12). The incidence of nausea and emesis 24 h after surgery was 30% (n = 12) and 7.5% (n = 3), respectively. The mean time to first emetic episode, first rescue, and first significant nausea was 31.3 (±33.6), 15.1 (±25.8), and 21.1 (±25.4) hours, respectively. The overall incidence of nausea and vomiting after 24-120 h period after surgery was 30% (n = 12). The percentage of subjects without emesis episodes over 24-120 h postoperatively was 70% (n = 28). No subjects presented a prolonged QTc interval ≥500 ms before and/or after surgery.

Conclusion: Our data demonstrated that this triple therapy regimen may be an adequate alternative regimen for the treatment of PONV in patients undergoing neurological surgery under general anesthesia. More studies with a control group should be performed to demonstrate the efficacy of this regimen and that palonosetron is a low risk for QTc prolongation.

Clinicaltrialsgov identifier: NCT02635828 (https://ichgcp.net/clinical-trials-registry/NCT02635828).

Keywords: QTc; emesis; nausea; postoperative complications; vomiting.

Figures

Figure 1
Figure 1
Patient screening flowchart.

References

    1. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth (2002) 89(3):409–23.10.1093/bja/89.3.409
    1. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs (2000) 59(2):213–43.10.2165/00003495-200059020-00005
    1. Gupta K, Singh I, Gupta PK, Chauhan H, Jain M, Rastogi B. Palonosetron, ondansetron, and granisetron for antiemetic prophylaxis of postoperative nausea and vomiting – a comparative evaluation. Anesth Essays Res (2014) 8(2):197–201.10.4103/0259-1162.134503
    1. Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth (2012) 109(5):742–53.10.1093/bja/aes276
    1. Kovac AL. Update on the management of postoperative nausea and vomiting. Drugs (2013) 73(14):1525–47.10.1007/s40265-013-0110-7
    1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg (2014) 118(1):85–113.10.1213/ANE.0000000000000002
    1. Wiesmann T, Kranke P, Eberhart L. Postoperative nausea and vomiting – a narrative review of pathophysiology, pharmacotherapy and clinical management strategies. Expert Opin Pharmacother (2015) 16(7):1069–77.10.1517/14656566.2015.1033398
    1. Muchatuta NA, Paech MJ. Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag (2009) 5(1):21–34.10.2147/TCRM.S3437
    1. Smith HS, Smith EJ, Smith BR. Postoperative nausea and vomiting. Ann Palliat Med (2012) 1(2):94–102.10.3978/j.issn.2224-5820.2012.07.05
    1. Latz B, Mordhorst C, Kerz T, Schmidt A, Schneider A, Wisser G, et al. Postoperative nausea and vomiting in patients after craniotomy: incidence and risk factors. J Neurosurg (2011) 114(2):491–6.10.3171/2010.9.JNS10151
    1. Bergese SD, Antor MA, Uribe AA, Yildiz V, Werner J. Triple therapy with scopolamine, ondansetron, and dexamethasone for prevention of postoperative nausea and vomiting in moderate to high-risk patients undergoing craniotomy under general anesthesia: a pilot study. Front Med (2015) 2:40.10.3389/fmed.2015.00040
    1. Park JW, Jun JW, Lim YH, Lee SS, Yoo BH, Kim KM, et al. The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting. Korean J Anesthesiol (2012) 63(4):334–9.10.4097/kjae.2012.63.4.334
    1. Ryoo SH, Yoo JH, Kim MG, Lee KH, Kim SI. The effect of combination treatment using palonosetron and dexamethasone for the prevention of postoperative nausea and vomiting versus dexamethasone alone in women receiving intravenous patient-controlled analgesia. Korean J Anesthesiol (2015) 68(3):267–73.10.4097/kjae.2015.68.3.267
    1. Perron G, Dolbec P, Germain J, Béchard P. Perineal pruritus after iv dexamethasone administration. Can J Anaesth (2003) 50(7):749–50.10.1007/BF03018722
    1. Deitrick CL, Mick DJ, Lauffer V, Prostka E, Nowak D, Ingersoll G. A comparison of two differing doses of promethazine for the treatment of postoperative nausea and vomiting. J Perianesth Nurs (2015) 30(1):5–13.10.1016/j.jopan.2014.01.009
    1. Tricco AC, Soobiah C, Hui W, Antony J, Struchkov V, Hutton B, et al. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review. BMC Pharmacol Toxicol (2015) 16(1):1.10.1186/2050-6511-16-1
    1. Kang JW, Park SK. Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting. Korean J Anesthesiol (2014) 67(2):110–4.10.4097/kjae.2014.67.2.110
    1. Zhou M, Popovic M, Pasetka M, Pulenzas N, Ahrari S, Chow E, et al. Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron. Ther Clin Risk Manag (2015) 11:713–29.10.2147/TCRM.S68130
    1. Roberts SM, Bezinover DS, Janicki PK. Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res (2012) 4:67–73.10.2147/JEP.S23105
    1. Pharma M. Aloxi (Palonosetron HCl Injection) [Package Insert]. Bloomington, MN: MGI Pharma; (2004). 2006 p.
    1. Schnell FM, Coop AJ. An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the FDA combined spontaneous reporting system/adverse event reporting system. Curr Ther Res Clin Exp (2005) 66(5):409–19.10.1016/j.curtheres.2005.10.003
    1. Garg A, Lehmann MH. Prolonged QT interval diagnosis suppression by a widely used computerized ECG analysis system. Circ Arrhythm Electrophysiol (2013) 6(1):76–83.10.1161/CIRCEP.112.976803
    1. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 55(9):934–47.10.1016/j.jacc.2010.01.001
    1. Lee J, In J. Effects of palonosetron on prolongation of corrected QT intervals may be less than reliable. Korean J Anesthesiol (2014) 66(4):327–8.10.4097/kjae.2014.66.4.327
    1. Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol (2013) 76(1):48–57.10.1111/bcp.12040
    1. Min JJ, Yoo Y, Kim TK, Lee JM. Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy. Korean J Anesthesiol (2013) 65(5):397–402.10.4097/kjae.2013.65.5.397
    1. Chun H, Jeon I, Park S, Lee S, Kang S, Kim S. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial. Br J Anaesth (2014) 112(3):485–90.10.1093/bja/aet340
    1. Mansour EE. Postoperative nausea and vomiting prophylaxis: the efficacy of a novel antiemetic drug (palonosetron) combined with dexamethasone. Egypt J Anaesth (2013) 29(2):117–23.10.1016/j.egja.2012.11.001
    1. Morganroth J, Flaharty KK, Parisi S, Moresino C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer (2015) 24(2):621–7.10.1007/s00520-015-2822-6

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner